Refine
Has Fulltext
- no (1)
Year of publication
- 2017 (1)
Document Type
- Other (1) (remove)
Language
- English (1) (remove)
Is part of the Bibliography
- yes (1)
Institute
New data from the LEADER trial show that the glucagon-like peptide 1 receptor agonist liraglutide protects against diabetic nephropathy in patients with type 2 diabetes mellitus. The renoprotective efficacy of liraglutide is not, however, as great as that reported for the sodium-glucose cotransporter 2 inhibitor emplagiflozin in the EMPA-REG OUTCOME trial.